Cellebrite DI Past Earnings Performance
Past criteria checks 0/6
Cellebrite DI's earnings have been declining at an average annual rate of -70.5%, while the Software industry saw earnings growing at 22% annually. Revenues have been growing at an average rate of 17.9% per year.
Key information
-70.48%
Earnings growth rate
-67.49%
EPS growth rate
Software Industry Growth | 17.33% |
Revenue growth rate | 17.91% |
Return on equity | -53.44% |
Net Margin | -46.34% |
Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Cellebrite: Near-Term Growth Is A Key Concern
May 27Cloud-Ready AI And Inseyets Migration Will Expand Digital Capabilities
Shift to cloud-based AI platforms and expansion in digital investigations are set to boost revenue through subscription services and high-margin solutions.Cellebrite DI: A Compounder But Not Yet Priced For Conviction Buy
Apr 24Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 16Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation
Feb 04A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)
Jan 10Cellebrite: There Are Potential Risks That Could Damper Growth
Nov 08Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?
Oct 30There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased
Sep 10Cellebrite: Rating Downgrade As Valuation Has Caught Up
Aug 27Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up
Aug 17Why We're Not Concerned About Cellebrite DI Ltd.'s (NASDAQ:CLBT) Share Price
Jun 25Is Cellebrite DI Ltd. (NASDAQ:CLBT) Potentially Undervalued?
May 21Cellebrite: Big Fish In A Small Pond
Apr 29Cellebrite DI Ltd.'s (NASDAQ:CLBT) P/S Is Still On The Mark Following 28% Share Price Bounce
Mar 14Cellebrite DI Ltd. (NASDAQ:CLBT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$13.17
Feb 18There's Reason For Concern Over Cellebrite DI Ltd.'s (NASDAQ:CLBT) Price
Jan 28Is Cellebrite DI Ltd. (NASDAQ:CLBT) Trading At A 39% Discount?
Nov 04Calculating The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)
May 26Revenue & Expenses Breakdown
How Cellebrite DI makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 25 | 419 | -194 | 190 | 102 |
31 Dec 24 | 401 | -283 | 183 | 98 |
30 Sep 24 | 385 | -317 | 175 | 95 |
30 Jun 24 | 362 | -103 | 166 | 89 |
31 Mar 24 | 343 | -112 | 161 | 86 |
31 Dec 23 | 325 | -81 | 154 | 84 |
30 Sep 23 | 306 | -64 | 145 | 82 |
30 Jun 23 | 294 | -42 | 145 | 84 |
31 Mar 23 | 280 | 20 | 142 | 82 |
31 Dec 22 | 271 | 116 | 138 | 81 |
30 Sep 22 | 265 | 165 | 138 | 80 |
30 Jun 22 | 259 | 152 | 142 | 75 |
31 Mar 22 | 255 | 122 | 132 | 70 |
31 Dec 21 | 246 | 70 | 124 | 66 |
30 Sep 21 | 236 | 7 | 118 | 61 |
30 Jun 21 | 223 | 7 | 98 | 58 |
31 Mar 21 | 209 | 2 | 96 | 56 |
31 Dec 20 | 195 | -9 | 92 | 54 |
31 Dec 19 | 172 | -10 | 91 | 47 |
Quality Earnings: CLBT is currently unprofitable.
Growing Profit Margin: CLBT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLBT is unprofitable, and losses have increased over the past 5 years at a rate of 70.5% per year.
Accelerating Growth: Unable to compare CLBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLBT is unprofitable, making it difficult to compare its past year earnings growth to the Software industry (20.5%).
Return on Equity
High ROE: CLBT has a negative Return on Equity (-53.44%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/06/09 08:55 |
End of Day Share Price | 2025/06/09 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellebrite DI Ltd. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tomer Zilberman | BofA Global Research |
Tyler Radke | Citigroup Inc |
Jeffrey Van Rhee | Craig-Hallum Capital Group LLC |